Home | Business News | CBJ Newsmakers | ExCellThera’s lead technology, ECT-001, receives FDA Regenerative Medicine Advanced Therapy (RMAT) designation ExCellThera’s lead technology, ECT-001, receives FDA Regenerative Medicine Advanced Therapy (RMAT) designation CBJ Newsmakers RecommendedWorkers overwhelmingly vote to strike at Ontario Teachers’ Pension Plan owned Wine Rack storesAmerican Lithium Completes Merger with PlateauSavaria Announces 2021 Q1 Results: Revenue up 27% and Adjusted EBITDA up 40%
